ClinicalTrials.gg
Status unknownNCT02334293Updated Jan 8, 2015

Omegaven® as Parenteral Nutrition

An interventional study of Omegaven in Cholestasis, sponsored by Carle Foundation Hospital. Status unknown at 1 site in United States. Open to participants aged 14 Days to 4 Months. Per ClinicalTrials.gov, last updated 2015-01-08.

Sponsored by Carle Foundation Hospital · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
14 Days to 4 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing fish oil triglycerides in Cholestasis — none open to participants now, none under way, none of them phase 3. fish oil triglycerides · Cholestasis.

Planned enrollment
8th of 14
25 · median 31
Started
2013
the only one that year
No phase
3 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
Carle Foundation Hospital

Among the 14 studies testing fish oil triglycerides in Cholestasis, this one is the 8th largest by planned enrollment, is the only one that started in 2013, is one of 3 with no phase, and was the 12th registered.

Cholestasis

150 studies on the registry are indexed under Cholestasis; 18 are open to participants now.

Browse Cholestasis studies →

Open to participants now

None of the 14 studies testing fish oil triglycerides in Cholestasis is open now. The open studies under Cholestasis, anywhere →

Where they have run

About fish oil triglycerides

fish oil triglycerides: first FDA approval 2018 (OMEGAVEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 9 Cholestasis studies recruiting now, 1 sets no upper age limit and 8 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 14 Days to 4 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing fish oil triglycerides in Cholestasis as a file.
02

Study summary

The purpose of this study is to determine if a fat emulsion comprised of omega-3 fatty acids, Omegaven, would be beneficial in the management of steatotic liver injury in parenteral nutrition (PN) by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum.

03

Conditions studied

  • Cholestasis

Keywords

  • Omegaven
  • parenteral nutrition
  • liver disease
  • liver injury
04

Who can participate

Ages eligible
14 Days to 4 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Greater than 14 days old.
  • Have PN-associated cholestasis defined as at least 2 consecutive direct >2 mg/dL with anatomical or functional short gut (OR >4 mg/dL if intact intestine) obtained at least 1 week apart with a ratio of direct: total bilirubin > 0.4.
  • Patients will be PN dependent (unable to meet nutritional needs solely by enteral nutrition) and are expected to require PN for at least 4 more weeks.
  • Patients must have failed standard therapies for Parenteral Nutrition Associated Liver Disease (PNALD) including: cycling of PN, avoiding overfeeding, reduction/removal of copper and manganese from PN, advancement of enteral feeding, and use of ursodiol (i.e. Actigall).
  • Signed patient .
  • The patient is expected to have a reasonable possibility of survival.
  • No other known etiology of cholestasis other than PNALD at time of Omegaven® initiation.

Exclusion criteria

Exclusion Criteria:

  • Causes of cholestasis other than PNALD including but not limited to , Cystic fibrosis, biliary atresia, and alpha 1 anti-trypsin deficiency, prior to Omegaven® initiation.
  • Known fish or egg allergy
  • Any of the to use of Omegaven®:

    1. Active new infection at the time of initiation of Omegaven®
    2. Hemodynamic instability
    3. Use of medications with associated risk of bleeding, including nonsteroidal antiinflammatory drugs (NSAIDs)
    4. Active coagulopathy or bleeding
    5. Thrombocytopenia
    6. Unstable hyperglycemia
    7. Impaired lipid metabolism (triglycerides >1000 mg/dL) while on 1 g/kg/day or less of Intralipid
    8. History of severe hemorrhagic disorders (ie. hemophilia, Von Willebrand disease, etc.)
    9. Unstable diabetes mellitus
    10. Collapse and shock
    11. Stroke/ Embolism
    12. Cardiac infarction within the last 3 months
    13. Undefined coma status
  • Enrollment in a clinical trial involving an agent (unless approved by the designated physicians on the multidisciplinary team)
  • The parent or guardian of child is unwilling to provide consent or assent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Other
    Omegaven

    Drug: Omegaven

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Outcomes/Endpoints ( time from baseline until the patient normalizes bilirubin (presents three consecutive direct bilirubin ≤ 2 mg/dL or a direct bilirubin ≤ 2 mg/dL and weaned from PN)

    Primary efficacy analysis will include time from baseline until the patient normalizes bilirubin (presents three consecutive direct bilirubin ≤ 2 mg/dL or a direct bilirubin ≤ 2 mg/dL and weaned from PN).

    Time frame: Until weaned from PN

Secondary outcomes

  1. Growth (weight three times per week, length once weekly, and head circumference)

    At a minimum, monitoring of growth parameters while on Omegaven® will include weight three times per week, length once weekly, and head circumference once weekly.

    Time frame: Until weaned from PN

  2. Essential Fatty Acids (evidence of essential fatty acid (EFA) deficiency)

    We will monitor infants who are not receiving any enteral feeding at all for more than 4 weeks for any evidence of essential fatty acid (EFA) deficiency.

    Time frame: Until weaned from PN

07

Study locations

1 of 1 sites recruiting
  • Carle Foundation Hospital
    Urbana, Illinois 61801, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013 and a primary completion of Jul 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2015
First posted
Jan 8, 2015
Start
Oct 2013
Primary completionEst.
Jul 2017
Last update
Jan 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02334293
Lead sponsor
Carle Foundation Hospital
Responsible party
Sponsor
First posted
Jan 8, 2015
Start date
Oct 2013
Primary completion
Jul 2017 (estimated)
Last update
Jan 8, 2015

Study contacts

Deveine Toney
Contact
deveine.toney@carle.com
(217) 326-4504
Mary Baker
Contact
clinicaltrials@carle.com
(217)326-0058
William Stratton, MD
principal investigator · Carle Foundation Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fish oil triglycerides

Start the discussion